|  | Field study I | Field study II | ||||||
---|---|---|---|---|---|---|---|---|---|
Sample population | Cancer survivors | Cancer survivorsa | Cancer survivorsb | Healthy Employeesc | |||||
Sample size | N = 302 | N = 130 | N = 87 | N = 45 | |||||
Demographic characteristics | Â | Â | Â | Â | |||||
Age (mean in years ± standard deviation) | 52 ± 8 | 52 ± 8 | 52 ± 9 | 51 ± 9 | |||||
 | N | (%) | N | (%) | N | (%) | N | (%) | |
Gender - male | 83 | (28) | 26 | (20) | 17 | (20) | 9 | (20) | |
Marital status | Married/living together with a partner | 240 | (79) | 106 | (82) | 69 | (79) | 38 | (82) |
Ethnical background | Dutch | 279 | (92) | 123 | (95) | 82 | (94) | 43 | (96) |
Immigrant first and second generation | 21 | (7) | 7 | (5) | 5 | (6) | 2 | (4) | |
Clinical characteristics | |||||||||
Number of cancer diagnoses | 1 diagnosis | 256 | (85) | 109 | (84) | 75 | (86) | – | – |
≥ 2 diagnoses | 45 | (15) | 21 | (16) | 12 | (14) | – | – | |
Cancer diagnosisd | Breast cancer | 123 | (36) | 68 | (49) | 51 | (55) | – | – |
Gynecological cancer | 59 | (17) | 20 | (14) | 10 | (11) | – | – | |
Gastrointestinal cancer | 47 | (14) | 34 | (24) | 22 | (24) | – | – | |
Urological cancer | 36 | (11) | 0 | (0) | 0 | (0) | – | – | |
Hematological cancer | 26 | (8) | 4 | (3) | 3 | (3) | – | – | |
Head and neck cancer | 22 | (6) | 6 | (4) | 3 | (3) | – | – | |
Malignant melanomas | 10 | (3) | 5 | (4) | 2 | (2) | – | – | |
Others (e.g. metastases) | 17 | (5) | 3 | (2) | 2 | (2) | – | – | |
Most recent cancer diagnosis | < 1 year ago | 60 | (20) | 21 | (16) | 13 | (15) | – | – |
1–3 years ago | 162 | (54) | 63 | (49) | 41 | (47) | – | – | |
4–6 years ago | 55 | (18) | 43 | (33) | 30 | (35) | – | – | |
> 6 years ago | 24 | (8) | 3 | (2) | 3 | (3) | – | – | |
Current cancer treatment | Yes | 42 | (14) | 26 | (20) | 16 | (18) | – | – |
Cancer treatmentd | Surgery | 253 | (39) | 112 | (39) | 74 | (37) | – | – |
Radiotherapy | 152 | (23) | 60 | (21) | 45 | (22) | – | – | |
Chemotherapy | 150 | (23) | 74 | (26) | 53 | (26) | – | – | |
Hormone therapy | 67 | (10) | 34 | (12) | 23 | (11) | – | – | |
Othere | 31 | (5) | 8 | (3) | 8 | (4) | – | – | |
Co-morbidity | Yes | 76 | (25) | 39 | (30) | 23 | (26) | – | – |
Work characteristics | |||||||||
Education | Primary/secondary education | 55 | (18) | 24 | (18) | 18 | (21) | 5 | (11) |
Intermediate vocational education | 102 | (34) | 51 | (39) | 36 | (41) | 15 | (33) | |
Higher prof/academic education | 143 | (47) | 54 | (42) | 33 | (38) | 25 | (56) | |
Work contract | Permanent position | 225 | (75) | 91 | (70) | 64 | (74) | 35 | (78) |
Temporary employment | 19 | (6) | 12 | (9) | 7 | (8) | 1 | (2) | |
Self-employed | 44 | (15) | 23 | (18) | 13 | (15) | 8 | (18) | |
Contract hours | <12Â h | 12 | (4) | 3 | (2) | 1 | (1) | 1 | (2) |
12–36 h | 141 | (47) | 80 | (62) | 57 | (66) | 32 | (71) | |
>36Â h | 112 | (37) | 32 | (25) | 19 | (22) | 9 | (20) | |
Current work hours | Total contract hours | 193 | (64) | 94 | (72) | 62 | (71) | – | – |
Proportion of contract hours (1–36) | 108 | (36) | 36 | (28) | 25 | (29) | – | – | |
Years on the job | 0–3 years | 36 | (12) | 20 | (15) | 12 | (14) | 7 | (16) |
4–7 years | 40 | (13) | 12 | (9) | 8 | (9) | 5 | (11) | |
> 8Â years | 225 | (74) | 67 | (77) | 98 | (75) | 33 | (74) | |
Management position | Yes | 78 | (26) | 25 | (19) | 17 | (20) | 8 | (18) |
Occupational sector | Health care and pharmacy | 73 | (24) | 38 | (29) | 26 | (30) | 12 | (27) |
Educational | 34 | (11) | 8 | (6) | 5 | (6) | 8 | (18) | |
Government | 30 | (10) | 14 | (11) | 11 | (13) | 4 | (9) | |
Industrial/production | 20 | (7) | 8 | (6) | 5 | (6) | 2 | (4) | |
Facility management | 12 | (4) | 4 | (3) | 2 | (2) | 1 | (2) | |
Wholesale/retail business | 15 | (5) | 9 | (7) | 7 | (8) | 3 | (7) | |
Transport/logistics | 16 | (5) | 6 | (5) | 4 | (5) | 1 | (2) | |
Business services | 26 | (9) | 16 | (12) | 8 | (9) | 6 | (13) | |
Juridical | 11 | (4) | 2 | (2) | 1 | (1) | 2 | (4) | |
IT | 7 | (2) | 4 | (3) | 3 | (3) | 1 | (2) | |
Other | 57 | (19) | 21 | (16) | 15 | (17) | 5 | (11) | |
Monthly income | ≤ €1000 | 46 | (15) | 21 | (16) | 13 | (15) | 6 | (13) |
€1001 - €3000 | 125 | (41) | 85 | (65) | 60 | (69) | 25 | (56) | |
≥ €3001 | 98 | (33) | 12 | (9) | 8 | (9) | 11 | (24) | |
Breadwinner position | Sole or shared | 251 | (83) | 99 | (76) | 68 | (78) | 35 | (78) |